信邦製藥(002390.SZ)正籌劃定增事項或涉控制權變更 明起停牌
格隆匯 8 月 31日丨信邦製藥(002390.SZ)公佈,公司正在籌劃非公開發行股票事項,發行股票數量不超過此次發行前公司總股本的20%,認購對象為公司董事長之一致行動人。該事項可能涉及公司控制權變更;同時,根據《上市公司收購管理辦法》的相關規定,該事項構成上市公司管理層收購,應當聘請符合《中華人民共和國證券法》規定的資產評估機構提供公司資產評估報告。該事項尚需公司董事會、股東大會審議通過以及相關監管部門的審批。
經公司向深圳證券交易所申請,公司股票自2020年9月1日上午開市起停牌,預計停牌時間不超過5個交易日。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.